Related Experiment Video
Updated: May 28, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
Published on: December 16, 2019
Testosterone replacement therapy and polycythemia in HIV-infected patients
Charles Kyriakos Vorkas1, Carlos M Vaamonde, Marshall J Glesby
1Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
None:
We conducted a case-control study to assess testosterone use as a primary risk factor for polycythemia in 21 HIV-infected men. Any testosterone use within 2 months of first elevated hemoglobin was associated with polycythemia (matched odds ratio 6.55; 95% confidence interval 1.83-23.4; P = 0.004) and intramuscular administration demonstrated a stronger association than topical use. No adverse cardiovascular or thrombotic events were observed. HIV-infected patients taking testosterone should undergo routine hematologic monitoring with adjustment of therapy when appropriate.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Sexually Transmitted Infections
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Affecting Factors
Cryptococcal Meningitis
